Passage Bio (PASG) to Release Quarterly Earnings on Monday

Passage Bio (NASDAQ:PASG) is expected to issue its quarterly earnings data before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Passage Bio Trading Up 1.6 %

PASG stock opened at $0.52 on Friday. The stock has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.65. Passage Bio has a 12-month low of $0.45 and a 12-month high of $1.79. The company has a market cap of $32.00 million, a PE ratio of -0.44 and a beta of 1.54.

Analyst Upgrades and Downgrades

PASG has been the subject of a number of research reports. Wedbush initiated coverage on Passage Bio in a research report on Friday, November 29th. They set an “outperform” rating and a $4.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Passage Bio in a research report on Thursday, November 14th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $13.00 target price on shares of Passage Bio in a research report on Thursday, November 14th.

Insider Transactions at Passage Bio

In other Passage Bio news, major shareholder Lynx1 Capital Management Lp purchased 373,645 shares of Passage Bio stock in a transaction that occurred on Friday, December 27th. The stock was purchased at an average price of $0.65 per share, with a total value of $242,869.25. Following the completion of the acquisition, the insider now owns 9,256,953 shares of the company’s stock, valued at approximately $6,017,019.45. This trade represents a 4.21 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 76,200 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $0.79, for a total value of $60,198.00. Following the completion of the transaction, the insider now directly owns 7,718,369 shares of the company’s stock, valued at $6,097,511.51. This represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 620,368 shares of company stock valued at $421,921 over the last quarter. Company insiders own 4.30% of the company’s stock.

Passage Bio Company Profile

Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.